Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eye Care Firms Ride New Products, Overseas Growth To Fuel Stocks In 2004

This article was originally published in The Gray Sheet

Executive Summary

Contact lens manufacturers The Cooper Companies and Bausch & Lomb are taking aim at the Asian specialty lens market to sustain growth experienced in 2003, following a rebound in stock prices for ophthalmic device manufacturers after a two-year lull
Advertisement

Related Content

Visx Eyes Expanded CustomVue Indications, Readies U.S. Presbyopia Trial
Visx Eyes Expanded CustomVue Indications, Readies U.S. Presbyopia Trial
Ocular Sciences Acquisition Puts Ciba, J&J/Vistakon In Cooper’s Sights
CooperVision Takes Aim At Ciba’s Specialty Contact Lens Leadership Position
IPO Flurry In 2004? Aspirants Stress Profitability, Economic Upturn As Key
Quidel, Digene Among Diagnostic Stocks To Rebound, Excel In 2003
B&L Expanded Drug-Delivery Products Seen As Springboard To Future Growth
Wesley Jessen Wins PureVision Patent Suit; B&L Weighs Limited Options
Wesley Jessen Wins PureVision Patent Suit; B&L Weighs Limited Options
Boston Scientific Toasts 2003 On Heels Of 76% Stock Leap; Index Hungover
Advertisement
UsernamePublicRestriction

Register

MT019559

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel